Patent Application
20110003759
The present invention relates to non-basic melanin concentrating hormone receptor-1 (MCHR1) antagonists, pharmaceutical compositions containing MCHR1 antagonists and methods of treating diabetes, obesity and related diseases employing such MCHR1 antagonists.
Several lines of pharmacological and genetic evidence support the role of Melanin Concentrating Hormone Receptor-1 (hereafter “MCHR1”) as a modulator of food intake and body weight. Central administration of melanin concentrating hormone (MCH) increases food intake and body weight both in rats and in mice. Chronic ICV infusion of MCH causes increased food intake and ultimately obesity in mice, while infusion of an MCH peptide antagonist blocks MCH-induced food intake and results in weight loss and decreased feeding in diet-induced obese mice.
The expression of both the MCH peptide and receptor are modulated by nutritional status. MCH mRNA is upregulated both in hyperphagic obese mice (ob/ob), and fasted animals. Targeted disruption of the gene for MCH peptide results in hypophagia and leanness. Disruption of the MCHR1 gene causes leanness, altered metabolism, and hyperlocomotion accompanied by mild hyperphagia. Conversely, over-expression of MCH peptide results in hyperphagia, obesity and diabetes. Small molecule MCHR1 antagonists have been shown to cause weight loss in rodent weight and feeding models after both oral and intraperitoneal administration; Eur. J. Pharmacol., 438:129-135 (2002), Nat. Med., 8:825-830 (2002), Eur. J. Pharmacol., 497:41-47 (2004).
Numerous non-peptide MCHR1 antagonists have been disclosed. The scope of the genus for each reflects a common perception regarding the criteria required for ligand recognition as MCHR1 agonists. A recent review of MCHR1 patent disclosures emphasized the commonality of these structures by the following description; “Ubiquitous throughout the MCH patent literature are molecules consisting of a central scaffold to which linkers to an aryl or heteroaryl group and a basic amino functionality are attached.” (Kowalski, T. J. et al., Expert Opin. Investig. Drugs, 13:1113-1122 (2004)). Pharmacophore models of these geni consistently envision a presumed prerequisite electrostatic interaction between a basic amine center of the antagonist ligand and aspartic acid 123 of the receptor which presumably is envisaged to emulate the mandatory interaction between arginine 14 of MCH peptide agonists with aspartic acid 123 of the MCHR1 receptor. (Ulven, T., J. Med. Chem., 48:5684-5697 (2005)) However, incorporation of this basic amine in a MCHR1 antagonist increases substantially the probability of binding to off-target ion-channels and biogenic amine receptors.
In accordance with the present invention, there is provided a series of novel high affinity selective MCHR1 antagonists for which binding affinity is not dependent upon inclusion of a basic amine functionality that is common to most of the disclosed MCHR antagonists. As a consequence, the absence of the basic center greatly reduces the probability of off-target interactions such as binding to other biogenic amine receptors as well as binding to ion channels such as the HERG receptor in the heart. The reduction/abolition of affinity for the HERG receptor is especially important since ligand occupancy is associated with initiation of fatal arrhythmias.
In one embodiment of the present invention, a compound of the Formula I or a pharmaceutically acceptable salt thereof is provided
wherein
is a phenylene ring or a heteroaryl ring which is a monocyclic ring or a bicyclic ring which contains one or two nitrogen atoms or one oxygen atom;
R1 is Z—Y—X—, wherein
G is lower alkyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, cycloalkoxy, alkylcycloalkoxy, or cycloalkoxyalkyl;
each J is independently hydrogen, hydroxyl, CN, —SO2R7, —SR7, —SOR7, lower alkyl, lower alkoxy, CF3, CF3O—, —COOR5 (wherein R5 is H, C1-3 alkyl, or cycloalkyl), or —CO—NR5aR6 wherein R5a and R6 are each independently selected from H, C1-3 alkyl, or cycloalkyl, or R5a and R6 taken together can be propanediyl, butanediyl or pentanediyl to form with the N atom to which they are attached a 4-, 5- or 6-membered cyclic amine, such as azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, optionally substituted with substituents as set out for “heterocyclo”;
R7 is lower alkyl;
R3 is C1-6 alkyl, cycloalkyl, C1-6 alkoxy, halogen, hydrogen, —S—C1-6 alkyl, CN, CF3O, or CF3;
and wherein R2 and R3 can be taken together to form a 5- to 7-membered ring which is saturated, unsaturated, or partially unsaturated and may include an E heteroatom, which is O, or 0, 1 or 2 N atoms, which ring is substituted with one or two of —O-G-(J)m groups, wherein at least one J is OH, and optionally other substituents as set out for “alkyl”, “aryl”, or “heteroaryl”, such as alkyl and/or OH;
with the proviso that where
is a phenylene ring, E-G and R3 are not identical unsubstituted lower alkoxy groups, and when G is lower alkyl and J is H, R3 is not hydrogen; and
R8 and R9 are each independently hydrogen, halogen, or lower alkyl;
including esters thereof, prodrugs thereof, solvates thereof, and all stereoisomers thereof.
Any of the foregoing Z moieties may either be unsubstituted or substituted with 1, 2 or 3 of amino, halo, C1-6 alkyl, C1-3 alkylamino, di-C1-3 alkylamino, C1-3 alkoxy, C1-3 thioalkyl, C1-3 trifluoroalkoxy, trifluoromethyl, cycloalkyl, cycloalkoxy, or heteroaryl such as pyridyl or substituted with any of the substituents as set out for “aryl”, “heteroaryl”, or “alkyl”.
Examples of substituents for the J group in the form of a cyclic amine include but are not limited to lower alkyl, lower alkoxy, OH, CF3, or CF3O, or other substituents as set out for “alkyl” and “heteroaryl”.
In a further aspect of the invention, there is provided a pharmaceutical composition which contains a therapeutically effective amount of the compound of the invention Formula I as defined above, in association with a pharmaceutically acceptable carrier or diluent.
There is also provided a method for the treatment of diabetes, obesity and other related conditions involving the MCHR1 in a mammal (such as a human, dog or cat) in need thereof, which includes the steps of administering to the mammal a therapeutically effective amount of the compound of Formula I of the invention as defined above.
The invention also sets forth one or more methods for making the compound of Formula I of the invention. In one embodiment, there is provided a process for the preparation of the compound of Formula I of the invention, wherein the compound a
is reacted with the alkali metal salt of Z—Y—X1H (b) (X1═O or S), preferably Z—(CH2)n—X1H (n=0, 1, 2 or 3).
In another embodiment of the invention, there is provided a process for the preparation of the compound of Formula I of the invention, wherein the compound c
is reacted with Z—Y—X1H (b), preferably Z—(CH2)n—X1H (n=0, 1, 2 or 3), and preferably in the presence of an activating agent.
The present invention is directed to these, as well as other important ends, hereinafter described.
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I of the invention alone and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I of the invention as defined above.
Unless otherwise indicated, the term “lower alkyl” as may be employed herein alone or as part of another group includes both straight and branched chain hydrocarbons containing 1 to 8 carbons, and the terms “alkyl”, “alk”, “alkyl chain”, “alkylene”, or “alkylene chain” as may be employed herein alone or as part of another group includes both straight and branched chain hydrocarbons containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 2 free bonds and thus are linking groups, namely “alkylene”, as well as such groups including 1 to 4 substituents such as halo, for example F, Br, Cl or I or CF3, alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkyloxy, hydroxy, hydroxyalkyl, acyl, alkanoyl, heteroaryl, heteroaryloxy, cycloheteroalkyl, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio.
Unless otherwise indicated, the term “cycloalkyl” or “lower cycloalkyl” as may be employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, any one of which may optionally be a spiro substituted cycloalkyl, including monocycloalkyl, bicycloalkyl and tricycloalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,
as well as such groups including 2 free bonds and thus are linking groups, any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, nitro, cyano, thiol and/or alkylthio and/or any of the substituents set for “alkyl”.
Unless otherwise indicated, the term “cycloalkoxy” or “lower cycloalkoxy” as employed herein alone or as part of another group, represents a 4-, 5- or 6-membered saturated ring containing an oxygen in the ring and includes
as well as such groups including 2 free bonds and thus are linking groups, and which may be optionally substituted with 1 or two of any of the substituents as set out for cycloalkyl.
The term “heterocyclo”, “heterocycle”, “heterocyclyl”, “heterocyclic” or “cycloheteroalkyl” ring, as may be used herein, represents an unsubstituted or substituted stable 4- to 7-membered monocyclic ring system which may be saturated or unsaturated, preferably saturated or partially unsaturated, and which consists of carbon atoms, with one to four heteroatoms selected from nitrogen, oxygen or sulfur, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which the heterocyclic ring is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic groups include, but is not limited to, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, pyrrolyl, pyrrolidinyl, furanyl, thienyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isooxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, thiadiazolyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, oxadiazolyl,
and other heterocycles described in Katritzky, A. R. et al., eds., Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds, Pergamon Press, New York, N.Y., publ. (1984); and Katritzky, A. R. et al., eds., Comprehensive Heterocyclic Chemistry II: A Review of the Literature 1982-1995, Elsevier Science, Inc., Tarrytown, N.Y., publ. (1996); and references therein, as well as such groups including 2 free bonds and thus are linking groups, as well as such groups optionally substituted with 1 to 3 of F, Br, Cl or I or CF3, alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkyloxy, hydroxy, hydroxyalkyl, acyl, alkanoyl, heteroaryl, heteroaryloxy, cycloheteroalkyl, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl, and/or alkylthio.
The term “alkanoyl” as may be used herein alone or as part of another group refers to alkyl linked to a carbonyl group.
The term “halogen” or “halo” as may be used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine, with chlorine or fluorine being preferred.
The term “metal ion” refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.
Unless otherwise indicated, the term “aryl” or “Aryl” as may be employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings), for example
and as well as such groups including 2 free bonds and thus are linking groups, and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl, arylcarbonyl, arylalkenyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino and arylsulfonaminocarbonyl and/or any of the substituents for “alkyl” set out herein.
Unless otherwise indicated, the term “heteroaryl” as may be used herein alone or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur. Such rings may be fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl and include possible N-oxides as described in Katritzky, A. R. et al., eds., Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds, Pergamon Press, New York, N.Y., publ. (1984); and Katritzky, A. R. et al., eds., Comprehensive Heterocyclic Chemistry II: A Review of the Literature 1982-1995, Elsevier Science, Inc., Tarrytown, N.Y., publ. (1996); and references therein as well as such groups including 2 free bonds and thus are linking groups. Further, “heteroaryl”, as defined herein, may optionally be substituted with one or more substituents such as the substituents included above for “alkyl” and/or “aryl”. Examples of heteroaryl groups include the following:
and the like.
Unless otherwise indicated, the term “lower alkoxy”, “alkoxy”, “aryloxy” or “aralkoxy” as may be employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.
Unless otherwise indicated, the term “lower alkylthio”, alkylthio”, “arylthio” or “aralkylthio” as may be employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.
The term “polyhaloalkyl” as may be used herein refers to an “alkyl” group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF3CH2, CF3 or CF3CF2CH2.
The term “polyhaloalkyloxy” as may be used herein refers to an “alkoxy” or “alkyloxy” group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF3CH2O, CF3O or CF3CF2CH2O.
Unless otherwise indicated, the term “alkenyl” as used herein alone or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like. Optionally, said alkenyl group may be substituted with one or substituents, such as those substituents disclosed for alkyl.
Unless otherwise indicated, the term “alkynyl” as used herein alone or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like. Optionally, said alkynyl group may be substituted with one or substituents, such as those substituents disclosed for alkyl.
The term “cycloalkenyl” as employed herein alone or as part of another group refers to partially unsaturated cyclic hydrocarbons containing 3 to 12 carbons, preferably 5 to 10 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl. Optionally, said cycloalkenyl group may be substituted with one or substituents, such as those substituents disclosed for alkyl.
The term “bicycloalkyl” as employed herein alone or as part of another group includes saturated bicyclic ring groups such as, without limitation, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, and so forth.
The term “polycycloalkyl” as employed herein alone or as part of another group includes two or more cycloalkyl ring systems, as defined herein, wherein at least one carbon atom is a part of at least two separately identifiable ring systems. The polycycloalkyl group may contain bridging between two carbon atoms, for example, bicyclo[1.1.0]butyl, bicyclo[3.2.1]octyl, bicyclo[5.2.0]nonyl, tricycl[2.2.1.0.sup.1 ]heptyl, norbornyl and pinanyl. The polycycloalkyl group may contain one or more fused ring systems, for example, decalinyl (radical from decalin) and perhydroanthracenyl. The polycycloalkyl group may contain a spiro union, in which a single atom is the only common member of two rings, for example, spiro[3.4]octyl, spiro[3.3]heptyl and spiro[4.5]decyl.
The term “acyl” as employed herein by itself or part of another group, as defined herein, refers to an organic radical linked to a carbonyl
group; examples of acyl groups include a substituent group attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaryl, cycloalkanoyl, cycloheteroalkanoyl and the like.
“Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes, without limitation, instances where said event or circumstance occurs and instances in which it does not. For example, optionally substituted alkyl means that alkyl may or may not be substituted by those groups enumerated in the definition of substituted alkyl.
“Substituted,” as used herein, whether express or implied and whether preceded by “optionally” or not, means that any one or more hydrogen on the designated atom (C, N, etc.) is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. For instance, when a CH2 is substituted by a keto substituent (═O), then 2 hydrogens on the atom are replaced. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. Further, when more than one position in a given structure may be substituted with a substituent selected from a specified group, the substituents may be either the same or different at every position.
The designation or
attached to a ring or other group refers to a free bond or linking group.
The
group may be phenylene or a heteroaryl which is monocyclic or bicyclic and includes rings such as
with phenylene and pyridinyl being preferred.
The Formula I compound of the invention may have the structure
In the compound of Formula I of the invention, it is desired that
is phenylene or pyridinyl;
X is O or S; and/or
Y is a bond or an alkylene chain of 1, 2 or 3 atoms; and/or
Z is phenyl; or
Z is a heteroaryl such as pyridinyl or benzothiazole; and/or
R2 is E-G-J; and/or
E is O or S; and/or
G is a lower alkyl or alkylcycloalkyl; and/or
J is H, OH, SO2R7, lower alkyl, lower alkoxy, or CF3, more preferably OH; and/or
R3 is C1-6 alkyl, C1-6 alkoxy, H, or halo; and/or
R8 and R9 are independently H or CH3; and/or
wherein R2 and R3 can be taken together to form a 5- to 7-membered ring which is saturated, unsaturated, or partially unsaturated and may include an E heteroatom, which is O, or 0, 1 or 2 N atoms, which ring is substituted with one or two of —O-G-(J)m groups, wherein at least one J is OH and optionally other substituents as set out for “alkyl”, “aryl”, or “heteroaryl”, such as alkyl and/or OH.
The above groups may be substituted as indicated herein.
Examples of the various groups of the compounds of Formula I of the invention are set out below:
is phenylene or pyridinyl;
Z is
Y is a bond or alkylene such as methylene, or ethylene or propylene; and/or
X is S, O, SO, or SO2; and/or
J is
phosphate
and the corresponding Na salt thereof), and valine
and/or
m is 1 or 2; and/or
G is CH2, (CH2)2, (CH2)3,
cycloalkyl such as
cycloalkoxy such as
or alkylcycloalkyl such as
and/or
E is O; and/or
R3 is H, alkoxy such as CH3O, hydroxyalkyl such as HOCH2CH2—, alkyl such as CH3 or C2H5, halo such as F or Cl, CN, or hydroxyalkoxy such as HOCH2CH2O—; and/or
R2 and R3 can be optionally taken together to form a 5- or 6-membered unsaturated or aromatic ring containing one or two N atoms, which ring is optionally substituted with hydroxyalkyl such as
for example
or where R2 and R3 can be optionally taken together to form a 6-membered saturated, unsaturated or partially unsaturated O-containing ring, which ring is optionally substituted with hydroxyalkyl such as alkyl such as
CH3 and OH, for example
and/or
R8 is H, halo such as F and Cl, or alkyl such as methyl; and/or
R9 is H.
In a further embodiment of the compound of Formula I of the invention, X═O and
is phenylene or pyridinyl. In another embodiment, X═S and
is phenylene.
In a further embodiment in Formula I of the invention, Y is a bond. Also in a further embodiment, Y is methylene, ethylene or propylene. In addition, the alkyl chain or alkyl moiety in Y may be attached to the ortho-position of Z to generate a bicyclic moiety. In this embodiment, the bicyclic moiety is preferably 1-indanyl or 2-indanyl when Z is phenyl.
In a further embodiment, Z is selected from phenyl, naphthyl, pyridinyl, pyrazinyl, benzimidazolyl, benzothiazolyl, and benzoxazolyl, preferably phenyl and pyridinyl.
Furthermore, in the embodiment wherein R5 and R6 taken together form a 4-, 5- or 6-membered cyclic amine, it is preferred that this component be selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl.
Also preferred is the embodiment wherein R3 is C1-C6 alkoxy. Especially preferred is the embodiment wherein R3 is C1-C3 alkoxy or C1-C3 alkyl. Even more preferably, R3 is methoxy or methyl.
In one embodiment of the invention, R1 may be selected from the group consisting of:
It is also desirable that in Formula I, R2 is —O—2-hydroxy-propane, R3 is methoxy, and R1 is selected from the group consisting of:
In another embodiment of the invention, it is desirable that
is phenylene;
R2 is
or
R2 and R3 can be optionally taken together to form a 5- or 6-membered unsaturated or aromatic ring containing one or two N atoms, which ring is optionally substituted with hydroxyalkyl such as
for example
and
R3 is methoxy or methyl, and R1 is selected from the group consisting of:
Also desired is the prodrug embodiment, hereinafter described, wherein in Formula I,
R2 is E-G-hydroxyl-Pro-Drug or more preferably
R3 is methoxy; and
R1 is selected from
Also desired are compounds of Formula I wherein
is phenylene;
R1 is Z—Y—X— wherein
or alkylcycloalkyl such as
and
R3 is H, alkoxy such as CH3O, or alkyl such as CH3;
R8 and R9 are independently H or CH3; and
R2 and R3 can be optionally taken together to form a 5- or 6-membered unsaturated or aromatic ring containing one or two N atoms, which ring is optionally substituted with hydroxyalkyl such as
for example
In still more preferred compounds of Formula I,
is phenylene;
X is S;
Y is a bond or (CH2)2;
E-G-J is
R3 is CH3O or CH3;
R8 and R9 are each H; and
R2 and R3 can be optionally taken together to form a 5- or 6-membered unsaturated or aromatic ring containing one or two N atoms, which ring is optionally substituted with hydroxyalkyl such as
for example
Some preferred compounds of the invention include the following:
Also desired are compounds of Formula I wherein
is
R1 is Z—Y—X— wherein
so that R1 can be selected from:
R2 is -E-G-J wherein
R3 is alkoxy such as CH3O, alkyl such as CH3, or halo such as Cl; and
R8 and R9 are independently H or CH3.
In still more desired compounds of Formula I,
is
X is S;
Y is a bond or (CH2)2;
Z is
E-G-J is
and
R3 is CH3, H or Cl.
The compounds of Formula I according to the various embodiments herein described can be prepared as shown in the following non-limiting reaction schemes and description thereof, as well as relevant published literature procedures that may be used by one skilled in the art.
Scheme 1 below portrays a generalized reaction sequence for the synthesis of compounds of Formula I.
Compounds of Formula I, for which R1 is Z—Y—O or Z—Y—S and R2 does not contain a tertiary alcohol, can be prepared by condensation of compounds of Formula II in a solvent such as THF with alkali metal salts such as Na+ or K+ of compounds of Formula III. The alkali salts of compounds of Formula III had been previously prepared by addition of compounds of Formula III to a stirred dispersion of NaH or KH in a solvent such as THF under an inert atmosphere of N2 or Ar. Compounds of Formula II can be prepared by treatment of compounds of Formula IV with thionyl chloride in a solvent such as DMF. Compounds of Formula III are commercially available or may be readily prepared by one skilled in the arts.
Alternatively, a general synthesis of compounds of Formula I, for which R1 is Z—Y—O, Z—Y—S or Z—Y—NR4H, entails condensation of compounds of Formula IV with compounds of Formula III by stirring these components in a solvent such as DMF containing benzotriazo-1-yl-oxy-trispyrrolidinophosphonium hexafluoroborate (PyBOP) as an activating agent, DMAP and a hindered amine such as Et(iPr)2N. Other activating agents may be utilized by the skilled artisan.
Compounds of Formula IV can be prepared by heating compounds of Formula V to 120-150° C. in microwave in a 1:1.1 mixture of HOAc/TFA. Compounds of Formula V can be prepared by stirring compounds of Formula VI with 2,2-dimethoxyethylamine in a solvent such as EtOAc. Compounds of Formula VI can be prepared by treatment of compounds of Formula VII with ethyl oxalyl chloride in a mixture of EtOAC and water containing a weak base such as potassium carbonate. Compounds of Formula VII are either commercially available or can be prepared as described in U.S. Ser. No. 11/586,255.
Compounds of Formula I for which R1 is Z—Y—SO or Z—Y—SO2 can be prepared by treatment of compounds of Formula I where R1 is Z—Y—S with one or two equivalents of an oxidant such as m-chloroperbenzoic acid in a solvent such as CH2Cl2.
Alternatively compounds of formula I can be prepared as outlined in Scheme 2. by Cu catalyzed arylation of compounds of formula X by heating X with aryl halides or iodides of formula XI in a solvent such as dioxane containing a cuprous salt such as cuprous iodide along with potassium tribasic phosphate and a chelating agent such as N-methyl, N′-methyl ethylene diamine Compounds of formula X can be prepared by heating compounds of formula IX in TFA. Compounds of formula IX can be prepared by condensation of compound of Formula VIII with compounds of Formula III by stirring these components in a solvent such as DMF containing benzotriazo-1-yl-oxy-trispyrrolidinophosphonium hexafluoroborate (PyBOP) as an activating agent, DMAP and a hindered amine such as Et(iPr)2N. Compound of formula VIII is readily obtained from p-methoxybenzyl amine utilizing the chemistry described in Scheme 1. Aryl halides of formula XI are readily prepared by one skilled in the arts by alkylation of the corresponding commercially available halogenated phenol.
Other methods of preparing the compounds of Formula I are within the scope of the invention as well.
Prodrugs, Salts, Esters and Stereoisomers
The compounds of the invention also include “prodrugs”. The term “prodrug” as used herein encompasses both the term “prodrug esters” and the term “prodrug ethers”. The term “prodrug esters” as employed herein includes esters and carbonates formed by reacting one or more hydroxyls of compounds of Formula I with either alkyl, alkoxy, or aryl substituted acylating agents or phosphorylating agent employing procedures known to those skilled in the art to generate acetates, pivalates, methylcarbonates, benzoates, amino acid esters, phosphates, half acid esters such as malonates, succinates or glutarates, and the like. In certain embodiments, amino acid esters may be especially preferred.
Examples of such prodrug esters include
(R═H or isopropyl or other alkyl group) (for example,
(where R1 is H or an alkali metal such as Na), that is
The term “prodrug ethers” include both phosphate acetals and O-glucosides. Representative examples of such prodrug ethers include
The compounds of Formula I can also be present as salts, which are further within the scope of this invention. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred. If the compounds of Formula I have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid (phosphate ester) or a hydrohalic acid, with organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms, for example acetic acid, which are unsubstituted or substituted, for example, by halogen as chloroacetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic acid, glutamic acid, glycine, valine, lysine, or arginine), or benzoic acid, or with organic sulfonic acids, such as (C1-C4) alkyl or arylsulfonic acids which are unsubstituted or substituted, for example by halogen, for example methyl- or p-toluene-sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of Formula I having at least one acid group (for example COOH) can also form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono, di or tri-lower alkylamine, for example ethyl, tert-butyl, diethyl, diisopropyl, triethyl, tributyl or dimethyl-propylamine, or a mono, di or trihydroxy lower alkylamine, for example mono, di or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds of Formula I or their pharmaceutically acceptable salts, are also included.
Preferred salts of the compounds of Formula I which contain a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate, nitrate or acetate.
Preferred salts of the compounds of Formula I which contain an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines
All stereoisomers of the compounds of the invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present application can have asymmetric centers at any of the carbon atoms including any one of the R substituents. Consequently, compounds of Formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials.
When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.
The compounds of the present application can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to metabolic and eating disorders as well as conditions associated with metabolic disorders (e.g., obesity, diabetes, arteriosclerosis, hypertension, polycystic ovary disease, cardiovascular disease, osteoarthritis, dermatological disorders, impaired glucose hemostasis, insulin resistance, hypercholesterolemia, hypertriglyceridemia, choletithiasis, dislipidemic conditions, bulimia nervosa and compulsive eating disorders); sleep disorders; and psychiatric disorders, such as depression, anxiety, schizophrenia, substance abuse, cognition-enhancement and Parkinson's disease.
The compounds described in the present application could be used to enhance the effects of cognition-enhancing agents, such as acetylcholinesterase inhibitors (e.g., tacrine), muscarinic receptor-1 agonists (e.g., milameline), nicotinic agonists, glutamic acid receptor (AMPA and NMDA) modulators, and nootropic agents (e.g., piracetam, levetiracetam). Examples of suitable therapies for treatment of Alzheimer's disease and cognitive disorders for use in combination with the compounds of the present application include donepezil, tacrine, revastigraine, 5HT6, gamma secretase inhibitors, beta secretase inhibitors, SK channel blockers, Maxi-K blockers, and KCNQs blockers.
The compounds described in the present application could be used to enhance the effects of agents used in the treatment of Parkinson's Disease. Examples of agents used to treat Parkinson's Disease include: levadopa with or without a COMT inhibitor, antiglutamatergic drugs (amantadine, riluzole), alpha-2 adrenergic antagonists such as idazoxan, opiate antagonists, such as naltrexone, other dopamine agonists or transporter modulators, such as ropinirole, or pramipexole or neurotrophic factors such as glial derived neurotrophic factor (GDNF).
The present application includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of Formula I, alone or in combination with a pharmaceutical carrier or diluent. Optionally, compounds of the present application can be used alone, in combination with other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-obesity agents; anti-diabetic agents, appetite suppressants; cholesterol/lipid-lowering agents, HDL-raising agents, cognition enhancing agents, agents used to treat neurodegeneration, agents used to treat respiratory conditions, agents used to treat bowel disorders, anti-inflammatory agents; anti-anxiety agents; anti-depressants; anti-hypertensive agents; cardiac glycosides; and anti-tumor agents.
Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the melanin-concentrating hormone receptor (MCHR) antagonists in accordance with the application.
Examples of suitable anti-obesity agents for use in combination with the compounds of the present application include melanocortin receptor (MC4R) agonists, cannabinoid receptor modulators, growth hormone secretagogue receptor (GHSR) antagonists, galanin receptor modulators, orexin antagonists, CCK agonists, GLP-1 agonists, and other Pre-proglucagon-derived peptides; NPY1 or NPY5 antagonist, NPY2 and NPY4 modulators, corticotropin releasing factor agonists, histamine receptor-3 (H3) modulators, aP2 inhibitors, PPAR gamma modulators, PPAR delta modulators, acetyl-CoA carboxylase (ACC) inhibitors, 11-β-HSD-1 inhibitors, adinopectin receptor modulators; beta 3 adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Pat. Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, a thyroid receptor beta modulator, such as a thyroid receptor ligand as disclosed in WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio) and WO 00/039077 (KaroBio), a lipase inhibitor, such as orlistat or ATL-962 (Alizyme), serotonin receptor agonists, (e.g., BVT-933 (Biovitrum)), monoamine reuptake inhibitors or releasing agents, such as fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline, chlorphentermine, cloforex, clortermine, picilorex, sibutramine, dexamphetamine, phentermine, phenylpropanolamine or mazindol, anorectic agents such as topiramate (Johnson & Johnson), CNTF (ciliary neurotrophic factor)/Axokine® (Regeneron), BDNF (brain-derived neurotrophic factor), leptin and leptin receptor modulators, or cannabinoid-1 receptor antagonists, such as SR-141716 (Sanofi) or SLV-319 (Solvay).
Examples of suitable anti-diabetic agents for use in combination with the compounds of the present application include: insulin secretagogues or insulin sensitizers, which may include biguanides, sulfonyl ureas, glucosidase inhibitors, aldose reductase inhibitors, PPAR γ agonists such as thiazolidinediones, PPAR α agonists (such as fibric acid derivatives), PPAR δ antagonists or agonists, PPAR α/γ dual agonists, 11-β-HSD-1 inhibitors, dipeptidyl peptidase IV (DP4) inhibitors including saxagliptin, SGLT2 inhibitors including dapagliflozin and serglifozin, glycogen phosphorylase inhibitors, and/or meglitinides, as well as insulin, and/or glucagon-like peptide-1 (GLP-1), GLP-1 agonist, incretin modulators, AMP kinase activators, glucocortical antagonists, fructose b is 1,6-phosphatase inhibitors, glucokinase inhibitors and/or a PTP-1B inhibitor (protein tyrosine phosphatase-1B inhibitor).
The antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably metformin HCl. Where the antidiabetic agent is a biguanide, the compounds of the present application will be employed in a weight ratio to biguanide within the range from about 0.001:1 to about 10:1, preferably from about 0.01:1 to about 5:1.
The antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Pat. No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the beta-cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms. The oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Pat. No. 4,904,769) or miglitol (disclosed in U.S. Pat. No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.
The compounds of the present application may be employed in combination with a PPAR γ agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Pat. No. 5,594,016), Glaxo-Wellcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), N,N-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.
The compounds of the present application may also be employed with a PPARα/γ dual agonist such as MK-767/KRP-297 (Merck/Kyorin; as described in Yajima, K. et al., Am. J. Physiol. Endocrinol. Metab., 284:E966-E971 (2003)), AZ-242 (tesaglitazar; Astra-Zeneca; as described in Ljung, B. et al., J. Lipid Res., 43:1855-1863 (2002)); muraglitazar; or the compounds described in U.S. Pat. No. 6,414,002.
The compounds of the present invention may be employed in combination with anti-hyperlipidemia agents, or agents used to treat arteriosclerosis. An example of an hypolipidemic agent would be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Pat. No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Pat. No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Pat. No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Pat. Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Pat. No. 5,354,772, cerivastatin disclosed in U.S. Pat. Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Pat. Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, pitavastatin (Nissan/Sankyo's nisvastatin (NK-104) or itavastatin), disclosed in U.S. Pat. No. 5,011,930, Shionogi-Astra/Zeneca rosuvastatin (visastatin (ZD-4522)) disclosed in U.S. Pat. No. 5,260,440, and related statin compounds disclosed in U.S. Pat. No. 5,753,675, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Pat. No. 4,613,610, indene analogs of mevalonolactone derivatives as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl)pyran-2-ones and derivatives thereof as disclosed in U.S. Pat. No. 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed in French Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Pat. No. 4,686,237, octahydronaphthalenes such as disclosed in U.S. Pat. No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European Patent Application No. 0142146 A2, and quinoline and pyridine derivatives disclosed in U.S. Pat. Nos. 5,506,219 and 5,691,322. In addition, phosphinic acid compounds useful in inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.
The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α-phosphono-sulfonates disclosed in U.S. Pat. No. 5,712,396, those disclosed by Biller, et al., J. Med. Chem., 31:1869-1871 (1998) including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Pat. Nos. 4,871,721 and 4,924,024 and in Biller, S. A. et al., Current Pharmaceutical Design, 2:1-40 (1996).
In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by Ortiz de Montellano, P. et al., J. Med. Chem., 20:243-249 (1977), the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey et al., J. Am. Chem. Soc., 98:1291-1293 (1976), phosphinylphosphonates reported by McClard, R. W. et al., J. Am. Chem. Soc., 109:5544 (1987) and cyclopropanes reported by Capson, T. L., Ph.D., dissertation, June, 1987, Dept. Med. Chem., U. of Utah, Abstract, Table of Contents, pp. 16, 17, 40-43, 48-51, Summary.
Other hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Pat. No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (SECHOLEX, POLICEXIDE) and cholestagel (Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Pat. No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Pat. No. 4,027,009, and other known serum cholesterol lowering agents.
The other hypolipidemic agent may be an ACAT inhibitor (which also has anti-atherosclerosis activity) such as disclosed in, Drugs of the Future, 24:9-15 (1999), (Avasimibe); Nicolosi et al., “The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Atherosclerosis (Shannon, Irel.), 137(1):77-85 (1998); Ghiselli, G., “The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein”, Cardiovasc. Drug Rev., 16(1):16-30 (1998); Smith, C. et al., “RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor”, Bioorg. Med. Chem. Lett., 6(1):47-50 (1996); Krause, B. R. et al., Chapter 6: “ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals”, Inflammation: Mediators and Pathways, CRC Press, Inc., publ., Ruffolo, Jr., R. R. et al., eds., pp. 173-198 (1995); Sliskovic et al., “ACAT inhibitors: potential anti-atherosclerotic agents”, Curr. Med. Chem., 1(3):204-225 (1994); Stout et al., “Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N′-[(1-phenylcyclopentyl)-methyl]ureas with enhanced hypocholesterolemic activity”, Chemtracts: Org. Chem., 8(6):359-362 (1995), or TS-962 (Taisho Pharmaceutical Co. Ltd), as well as F-1394, CS-505, F-12511, HL-004, K-10085 and YIC-C8-434.
The hypolipidemic agent may be an upregulator of LDL receptor activity such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly). The hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's SCH48461 (ezetimibe) as well as those disclosed in Atherosclerosis, 115:45-63 (1995) and J. Med. Chem., 41:973 (1998).
The other lipid agent or lipid-modulating agent may be a cholesteryl transfer protein inhibitor (CETP) such as Pfizer's CP-529,414 as well as those disclosed in WO/0038722 and in EP 818448 (Bayer) and EP 992496, and Pharmacia's SC-744 and SC-795, as well as CETi-1 and JTT-705.
The hypolipidemic agent may be an ileal Na+/bile acid co-transporter inhibitor such as disclosed in Drugs of the Future, 24:425-430 (1999). The ATP citrate lyase inhibitor which may be employed in the combination of the application may include, for example, those disclosed in U.S. Pat. No. 5,447,954.
The other lipid agent also includes a phytoestrogen compound such as disclosed in WO 00/30665 including isolated soy bean protein, soy protein concentrate or soy flour as well as an isoflavone such as genistein, daidzein, glycitein or equol, or phytosterols, phytostanol or tocotrienol as disclosed in WO 2000/015201; a beta-lactam cholesterol absorption inhibitor such as disclosed in EP 675714; an HDL upregulator such as an LXR agonist, a PPAR α-agonist and/or an FXR agonist; an LDL catabolism promoter such as disclosed in EP 1022272; a sodium-proton exchange inhibitor such as disclosed in DE 19622222; an LDL-receptor inducer or a steroidal glycoside such as disclosed in U.S. Pat. No. 5,698,527 and GB 2304106; an anti-oxidant such as beta-carotene, ascorbic acid, α-tocopherol or retinol as disclosed in WO 94/15592 as well as Vitamin C and an antihomocysteine agent such as folic acid, a folate, Vitamin B6, Vitamin B12 and Vitamin E; isoniazid as disclosed in WO 97/35576; a cholesterol absorption inhibitor, an HMG-CoA synthase inhibitor, or a lanosterol demethylase inhibitor as disclosed in WO 97/48701; a PPAR δ agonist for treating dyslipidemia; or a sterol regulating element binding protein-I (SREBP-1) as disclosed in WO 2000/050574, for example, a sphingolipid, such as ceramide, or neutral sphingomyelenase (N-SMase) or fragment thereof. Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, pitavastatin and rosuvastatin, as well as niacin and/or cholestagel.
The compounds of the present invention may also be employed in combination with anti-hypertensive agents. Examples of suitable anti-hypertensive agents for use in combination with the compounds of the present application include beta adrenergic blockers, calcium channel blockers (L-type and/or T-type; e.g., diltiazem, verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone), renin inhibitors, ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril), AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan), ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265), Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors, vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilat and gemopatrilat), and nitrates.
MCHR1 antagonists could also be useful in treating other diseases associated with obesity, including sleep disorders. Therefore, the compounds described in the present application could be used in combination with therapeutics for treating sleep disorders. Examples of suitable therapies for treatment of sleeping disorders for use in combination with the compounds of the present application include melatonin analogs, melatonin receptor antagonists, ML 1 B agonists, GABA receptor modulators; NMDA receptor modulators, histamine-3 (H3) receptor modulators, dopamine agonists and orexin receptor modulators.
MCHR1 antagonists may reduce or ameliorate substance abuse or addictive disorders. Therefore, combination of cannabinoid receptor modulators with agents used to treat addictive disorders may reduce the dose requirement or improve the efficacy of current addictive disorder therapeutics. Examples of agents used to treat substance abuse or addictive disorders are: selective serotonin reuptake inhibitors (SSRI), methadone, buprenorphine, nicotine and bupropion.
MCHR1 antagonists may reduce anxiety or depression; therefore, the compounds described in this application may be used in combination with anti-anxiety agents or antidepressants. Examples of suitable anti-anxiety agents for use in combination with the compounds of the present application include benzodiazepines (e.g., diazepam, lorazepam, oxazepam, alprazolam, chlordiazepoxide, clonazepam, chlorazepate, halazepam and prazepam), 5HT1A receptor agonists (e.g., buspirone, flesinoxan, gepirone and ipsapirone), and corticotropin releasing factor (CRF) antagonists.
Examples of suitable classes of anti-depressants for use in combination with the compounds of the present application include norepinephrine reuptake inhibitors (tertiary and secondary amine tricyclics), selective serotonin reuptake inhibitors (SSRIs) (fluoxetine, fluvoxamine, paroxetine and sertraline), monoamine oxidase inhibitors (MAOIs) (isocarboxazid, phenelzine, tranylcypromine, selegiline), reversible inhibitors of monoamine oxidase (RIMAs) (moclobemide), serotonin and norepinephrine reuptake inhibitors (SNRIs) (venlafaxine), corticotropin releasing factor (CRF) receptor antagonists, alpha-adrenoreceptor antagonists, and atypical antidepressants (bupropion, lithium, nefazodone, trazodone and viloxazine).
The combination of a conventional antipsychotic drug with a MCHR1 antagonist could also enhance symptom reduction in the treatment of psychosis or mania. Further, such a combination could enable rapid symptom reduction, reducing the need for chronic treatment with antipsychotic agents. Such a combination could also reduce the effective antipsychotic dose requirement, resulting in reduced probability of developing the motor dysfunction typical of chronic antipsychotic treatment.
Examples of suitable antipsychotic agents for use in combination with the compounds of the present application include the phenothiazine (chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine), thioxanthine (chlorprothixene, thiothixene), heterocyclic dibenzazepine (clozapine, olanzepine and aripiprazole), butyrophenone (haloperidol), diphenylbutylpiperidine (pimozide) and indolone (molindolone) classes of antipsychotic agents. Other antipsychotic agents with potential therapeutic value in combination with the compounds in the present application include loxapine, sulpiride and risperidone.
Combination of the compounds in the present application with conventional antipsychotic drugs could also provide an enhanced therapeutic effect for the treatment of schizophrenic disorders, as described above for manic disorders.
As used here, schizophrenic disorders include paranoid, disorganized, catatonic, undifferentiated and residual schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder and psychotic disorder not specified. Examples of suitable antipsychotic drugs for combination with the compounds in the present application include the antipsychotics mentioned above, as well as dopamine receptor antagonists, muscarinic receptor agonists, 5HT2A receptor antagonists and 5HT2A/dopamine receptor antagonists or partial agonists (e.g., olanzepine, aripiprazole, risperidone, ziprasidone).
The compounds of the present invention can be administered in oral dosage form The dosage form for said pharmaceutical composition includes such oral dosage forms as granules, powders, tablets, capsules, syrups, emulsions, suspensions, etc. and such non-oral dosage forms as injections (e.g., subcutaneous, intravenous, intramuscular and intraperitoneal injections), drip infusions, external application forms (e.g., nasal spray preparations, transdermal preparations, ointments, etc.), and suppositories (e.g., rectal and vaginal suppositories).
These dosage forms can be manufactured by the per se known technique conventionally used in pharmaceutical procedures. The specific manufacturing procedures are as follows.
To manufacture an oral dosage form, an excipient (e.g., lactose, sucrose, starch, mannitol, etc.), a disintegrator (e.g., calcium carbonate, carboxymethylcellulose calcium, etc.), a binder (e.g., α-starch, gum arabic, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, etc.), and a lubricant (e.g., talc, magnesium stearate, polyethylene glycol 6000, etc.), for instance, are added to the active component or components and the resulting composition is compressed. Where necessary, the compressed product is coated, by the per se known technique, for masking the taste or for enteric dissolution or sustained release. The coating material that can be used includes, for instance, ethylcellulose, hydroxymethylcellulose, polyoxyethylene glycol, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, and Eudragit (Rohm & Haas, Germany, methacrylic-acrylic copolymer).
Injections can be manufactured typically by the following procedure. The active component or components are dissolved, suspended or emulsified in an aqueous vehicle (e.g., distilled water, physiological saline, Ringer's solution, etc.) or an oily vehicle (e.g., vegetable oil such as olive oil, sesame oil, cottonseed oil, corn oil, etc. or propylene glycol) together with a dispersant, e.g., Tween 80 (Atlas Powder, U.S.A.), HCO 60 (Nikko Chemicals), polyethylene glycol, carboxymethylcellulose, sodium alginate, etc.), a preservative (e.g., methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, benzyl alcohol, chlorobutanol, phenol, etc.), an isotonizing agent (e.g., sodium chloride, glycerol, sorbitol, glucose, inverted sugar, etc.) and other additives. If desired, a solubilizer (e.g., sodium salicylate, sodium acetate, etc.), a stabilizer (e.g., human serum albumin), a soothing agent (e.g., benzalkonium chloride, procaine hydrochloride, etc.) and other additives can also be added.
A dosage form for external application can be manufactured by processing the active component or components into a solid, semi-solid or liquid composition. To manufacture a solid composition, for instance, the active component or components, either as they are or in admixture with an excipient (e.g., lactose, mannitol, starch, microcrystalline cellulose, sucrose, etc.), a thickener (e.g., natural gums, cellulose derivatives, acrylic polymers, etc.), etc., are processed into powders. The liquid composition can be manufactured in substantially the same manner as the injections mentioned above. The semi-solid composition is preferably provided in a hydrous or oily gel form or an ointment form. These compositions may optionally contain a pH control agent (e.g., carbonic acid, phosphoric acid, citric acid, hydrochloric acid, sodium hydroxide, etc.), and a preservative (e.g., p-hydroxybenzoic acid esters, chlorobutanol, benzalkonium chloride, etc.), among other additives.
Suppositories can be manufactured by processing the active component or components into an oily or aqueous composition, whether solid, semi-solid or liquid. The oleaginous base that can be used includes, for instance, higher fatty acid glycerides [e.g., cacao butter, Witepsols (Dinamit-Nobel), etc.], medium-chain fatty acids [e.g., Migriols (Dinamit-Nobel), etc.], vegetable oils (e.g., sesame oil, soybean oil, cotton-seed oil, etc.), etc. The water-soluble base includes, for instance, polyethylene glycols propylene glycol, etc. The hydrophilic base includes, for instance, natural gums, cellulose derivatives, vinyl polymers, and acrylic polymers, etc.
The dosage of the pharmaceutical composition of the present invention may be appropriately determined with reference to the dosages recommended for the respective active components and can be selected appropriately according to the recipient, the recipient's age and body weight, current clinical status, administration time, dosage form, method of administration, and combination of the active components, among other factors. For example, the dosage of the compound of Formula I of the invention for a human adult can be selected from the clinical oral dose range of 0.01 to 30 mg/kg body weight (preferably 0.05 to 10 mg/kg body weight, more preferably 0.05 to 5 mg/kg body weight) or the clinical parenteral dose range of 0.005 to 10 mg/kg body weight (preferably 0.01 to 10 mg/kg body weight, more preferably 0.01 to 1 mg/kg body weight) or 1 to 1000 mg/day. The other active component or components having different modes of action for use in combination can also be used in dose ranges selected by referring to the respective recommended clinical dose ranges. Administration is generally carried out in a single dose/day or in divided doses, for example, 2 to 4 times a day.
The following abbreviations may be employed herein:
Ph=phenyl
Bn=benzyl
t-Bu=tertiary butyl
Me=methyl
Et=ethyl
TMS=trimethylsilyl
TBS=tert-butyldimethylsilyl
Et2O=diethyl ether
EtOAc=ethyl acetate
MeOH=methanol
EtOH=ethanol
i-PrOH=isopropanol
HOAc or AcOH=acetic acid
i-Pr2NEt=diisopropylethylamine
Et3N=triethylamine
DMAP=4-dimethylaminopyridine
NaBH4=sodium borohydride
n-BuLi=n-butyllithium
Pd/C=palladium on carbon
KOH=potassium hydroxide
NaOH=sodium hydroxide
LiOH=lithium hydroxide
K2CO3=potassium carbonate
NaHCO3=sodium bicarbonate
Ar=argon
N2=nitrogen
min=minute(s)
h or hr=hour(s)
L=liter
mL=milliliter
μL=microliter
g=gram(s)
mg=milligram(s)
mol=moles
mmol=millimole(s)
meq=milliequivalent
RT=room temperature
sat or sat' d=saturated
aq.=aqueous
TLC=thin layer chromatography
HPLC=high performance liquid chromatography
LC/MS=high performance liquid chromatography/mass spectrometry
MS or Mass Spec=mass spectrometry
NMR=nuclear magnetic resonance
mp=melting point
The following examples are provided to illustrate various preferred embodiments of the invention, and should not be construed as limiting the scope thereof.
General Experimental Information Section
In the following examples, nomenclature conforms to either IUPAC or CAS guidelines; was generated using (or is consistent with) the Autonom® module (version 2.1) distributed with ChemDraw Ultra 6.0®; or are taken from vendor literature.
brine=saturated aqueous sodium chloride
DIC=diisopropylcarbodiimide
PyBOP=benzotriazo-1-yl-oxy-trispyrrolidinophosphonium hexafluoroborate
TFA=trifluoroacetic acid
THF=tetrahydrofuranyl
WSC=1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride
HPLC: column:
Method 1: Phenom-Luna (ODS) S-5, 4.6 mm×50 mm; flow-5.0 mL/min.; detection at 220 nm; solvent-A=10% methanol/water+0.2% phosphoric acid, B=90% methanol/water+0.2% phosphoric acid; gradient-linear, 0% B to 100% B over 4 min and 100% B for 1 min.
Method 2: YMC Combiscreen S-5, 4.6 mm×50 mm; flow-4.0 mL/min.; detection at 220 nm; solvent-A=10% methanol/water+0.2% phosphoric acid, B=90% methanol/water+0.2% phosphoric acid; gradient-linear, 0% B to 100% B over 4 min and 100% B for 1 min.
LC MS: column-Phen-Luna (S5 ODS column) 4.6 mm×30 mm; detection at 220 nm; flow-4 mL/min; solvent-A=10% methanol/water+0.1% TFA, B=90% methanol/water+0.1% TFA; linear gradient, 0% B to 100% B over 2 min and 100% B for 1 min.
Phenomenex Luna C18, S5, 21×100 mm; flow-20 mL/min, detection at 220 nm; solvent-A=10% methanol/water+0.1% TFA, B=90% methanol/water+0.1% TFA; gradient-linear, 10% B to 90% B over 20 min.
Ethyl oxalyl chloride (7.8 g, 6.8 mL, 57 mmol) was added to a mixture of 3,4-dimethoxyaniline (4.4 g, 29 mmol) and K2CO3 (14 g, 140 mmol) in EtOAc (44 mL) and water (12 mL) at 0° C. After stirring at 0° C. for 10 min, water (18 mL) was added; whereupon the mixture was transferred to a separatory funnel and extracted with EtOAc (2×40 mL). The combined EtOAc were filtered through Na2SO4 and evaporated to about 30 mL. After addition of 2,2-dimethoxyethylamine (3.8 g, 3.9 mL, 36 mmol), the reaction was stirred at ambient temperature overnight. The resultant white solid was filtered and then washed with hexane to afford N1-(2,2-dimethoxyethyl)-N2-(3,4-dimethoxyphenyl)oxalamide as a light purple-grey solid (6.3 g, 71% yield). HPLC 33% 2.47 min and 63% at 2.79 min. LC MS 1.37 min (M+1=281 and 335). H-NMR (CDCl3) 9.15 (broad s, 1H), 7.76 (broad s, 1H), 7.41 (d, J=2.4 Hz, 1H), 7.06 (dd, J=2.4, 8.7 Hz, 1H), 6.85 (d, J=8.7 Hz, 1H), 4.45 (t, J=5.5 Hz, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 3.52 (t, J=5.5 Hz, 2H), 3.42 (s, 6H).
After addition of trifluoroacetic acid (0.12 mL, 1.7 mmol) to a mixture of the aryl oxalamide prepared in Part A (0.50 g, 1.6 mmol) in acetic acid (1.0 mL), the resulting solution was heated to 125° C. for 20 min using a microwave. Following evaporation of the solvent, the residue was triturated with EtOAc to afford 1-(3,4-dimethoxyphenyl)pyrazine-2,3(1H,4H)-dione as a white solid (1.1 g, 92% yield). HPLC 1.83 min. LC MS 1.20 min (M+1=249). H-NMR (CD3OD) 7.06 (m, 2H), 6.97 (m, 1H), 6.56 (d, J=5.7 Hz, 1H), 6.45 (d, J=5.7 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H).
Thionyl chloride (0.28 g, 0.17 mL, 2.4 mmol) was slowly added to a stirred solution of the 1-aryl pyrazine-2,3(1H,4H)-dione prepared in Part B (0.54 g, 2.2 mmol) in EtOAc (0.88 mL) and DMF (0.44 mL) at 45° C. After stirring at 55 to 60° C. for 2 h, the reaction was transferred to a separatory funnel, diluted with EtOAc and 2N KHCO3 and extracted with EtOAc (2×). The combined organic layers were washed with 2N KHCO3 and water; whereupon, the combined aqueous layers were extracted with CH2Cl2. All of the organic layers were combined prior to drying over MgSO4 to afford 3-chloro-1-(3,4-dimethoxyphenyl)pyrazin-2(1H)-one (0.34 g, 59% yield). HPLC 2.33 min. LC MS 1.00 min (M+1=267/269). The chloropyrazinone was used in the subsequent steps without further purification.
4-Chlorobenzylmercaptan (71 mg, 0.059 mL, 0.45 mmol) was added to a stirred THF (1.0 mL) suspension of sodium hydride (60% oil dispersion, 18 mg, 0.45 mmol), that had been previously washed with hexane 3×. The reaction was stirred at ambient temperature for 20 min until it became a solid mass; whereupon, the chloropyrazinone prepared in Part C (100 mg, 0.38 mmol) in THF (5 mL) was added resulting in gas evolution. After stirring at ambient temperature for 40 min, the reaction was diluted with CH2Cl2/H2O, extracted with CH2Cl2 (2×) and dried over MgSO4 to afford 220 mg of crude product after evaporation of the solvent. The desired was purified by chromatography on silica gel (12 g) employing gradient elution (0-100% EtOAc/hexane over 12 min) to elute the desired 3-(4-chlorobenzylthio)-1-(3,4-dimethoxyphenyl)pyrazin-2(1H)-one (130 mg, 89% yield).
A solution of the 1-aryl pyrazine-2,3(1H,4H)-dione prepared in Part B (67 mg, 0.27 mmol), diisopropylethyl amine (0.15 mL, 0.81 mmol), pyBOP (0.23 g, 0.46 mmol), and dimethylaminopyridine (13 mg) in DMF (1.2 mL) was stirred at ambient temperature for 15 min. After addition of 2-pyridylethyl mercaptan (28 mg, 0.40 mmol), the reaction was stirred at ambient temperature for 2.5 h prior to quenching by addition of H2O and extraction with EtOAc. The EtOAc extracts were washed with water (2×), brine, dried over MgSO4 and concentrated to yield 204 mg of crude product. Chromatography on silica employing a gradient elution with hexane/EtOAc afforded the desired product 1-(3,4-dimethoxyphenyl)-3-(2-(pyrazin-2-yl)ethylthio)pyrazin-2(1H)-one (17 mg, 17% yield).
The same procedure was employed as that described in Method 2 except that the reaction was run for 18 hr.
Following preparation of the oxalamide as described in Part A, ring closure can be effected by prolonged thermal heating in TFA/HOAc at 78° C. for 1d. In the case of 3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)aniline which contained a basic amine, the reaction was brought to pH 6 to 7 with saturated NaHCO3 and then evaporated in vacuo. The residue was absorbed on silica gel and purified by flash chromatography (5 to 15% 2N NH3 in MeOH/CH2Cl2) to afford the desired 1-aryl pyrazine-2,3(1H,4H)-dione in 36% yield. This material was subsequently converted to final product following the procedure described in Method 2.
If the oxalamide as described in Part A contained a primary or secondary alcohol, prolonged thermal heating in TFA/HOAc at 78° C. for 1 day not only effected ring closure but also converted the alcohol moiety to an acetate. The resulting 1-aryl pyrazine-2,3(1H,4H)-dione was converted to the desired 3-thio substituted-1-arylpyrazin-2-one employing Method 1. Following workup and purification as described in Method 1, the acetylated product was converted to the desired 3-thio substituted-1-arylpyrazin-2-one (19 mg, 0.041 mmol) bearing a free hydroxyl by dissolution in MeOH (1.0 mL) and H2O (0.1 mL) and stirring at ambient temperature for 1 h after addition of potassium carbonate (30 mg). The reaction was then diluted with CH2Cl2/H2O prior to extraction with CH2Cl2 (2×). After drying the combined organic layers over MgSO4, concentration afforded the desired final product (16 mg, 93% yield).
For weakly nucleophilic thiols more forcing conditions were required effect PyBOP mediated conversion of the 1-aryl pyrazine-2,3(1H,4H)-dione to a 3-thio substituted-1-arylpyrazin-2-ones. Accordingly, a DMF solution (0.4 mL) containing the 1-aryl pyrazine-2,3(1H,4H)-dione prepared in Part B (92 mg, 0.30 mmol), PyBOP (0.27 g, 0.53 mmol) and diisopropylethylamine (0.16 mL, 0.9 mmol) was stirred for 3 h before addition of a DMF solution prepared by stirring 5-methoxybenzo[d]thiazole-2-thiol (296 mg, 1.502 mmol) with NaH (60.1 mg, 1.502 mmol, rinsed with hexane 2×) in DMF (0.2 mL) at ambient temperature for 10 min. After stirring at ambient temperature for 7 days, the reaction mixture was diluted with EtOAc and washed sequentially with water (2×) and brine prior to drying over MgSO4. After evaporation of the solvent, CH2Cl2 (10 mL) was added to the 0.30 g of crude product. Filtration to remove any residual solids followed by evaporation of the filtrate afforded 0.10 g crude product. Final purification required flash chromatography on 12 g silica gel using gradient elution (0 to 100% EtOAc/CH2Cl2) followed by preparatory HPLC (YMC S5 ODS 20×100 mm, 20 mL/min, 30 to 100% B in A over 10 min, .Solvent A=10% MeOH/H2O-0.1% TFA, Solvent B=90% MeOH/H2O-0.1% TFA) to afford pure desired product (6.3 mg, 4% yield).
General Experimental Procedures for Preparation of 1-(4-(2-Hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one
To a mixture of (4-methoxyphenyl)methanamine (9.90 g, 72.2 mmol) in THF (40 mL) was slowly added ethyl 2-chloro-2-oxoacetate (10.84 g, 79 mmol). After stirring the reaction at RT for 15 min, a solution of 2,2-dimethoxyethanamine (9.10 g, 87 mmol) and N,N-diisopropylethylamine (37.8 mL, 217 mmol) in EtOAc (40.0 mL) was added. The reaction was heated at reflux for 18 hours; whereupon, after cooling to RT, saturated NaHCO3 (50 ml) was added and the mixture extracted with EtOAc (50 ml). The EtOAc layer was dried over Na2SO4 and concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (CH2Cl2 to 5% MeOH/CH2Cl2) to elute N1-(2,2-dimethoxyethyl)-N2-(4-methoxybenzyl)oxalamide (7.50 g, 25.3 mmol, 35.1% yield) as white solid. 1H NMR (400 MHz, chloroform-d) δ ppm 9.07 (1H, s), 7.69 (1H, t, J=5.65 Hz), 7.59 (1H, d, J=8.78 Hz), 6.74 (1H, d, J=8.78 Hz), 4.46 (1H, t, J=5.40 Hz), 3.79 (2H, s), 3.53 (2H, t), 3.44 (6H, s), 2.23 (6H, d, J=5.27 Hz), 1.37 (6H, s).
Part B. 3-Hydroxy-1-(4-methoxybenzyl)pyrazin-2(1H)-one
A solution of N1-(2,2-dimethoxyethyl)-N2-(4-methoxybenzyl)oxalamide (7.5 g, 25.3 mmol) and TFA (2.340 mL, 30.4 mmol) in AcOH (160 mL) was stirred at 135° C. in a seal tube for 1.5 hours. After cooling to RT and removal of the volatiles under vacuum, ethyl ether (150 ml) and sat. aq. NaHCO3 solution (150 ml) were added. The resulting precipitate was collected by filtration, washed with H2O (50 ml) and ether (50 ml) prior to drying under high vacuum to yield 3-hydroxy-1-(4-methoxybenzyl)pyrazin-2(1H)-one (5.30 g, 21.68 mmol, 86% yield) as brown solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.17 (1H, br. s.), 7.18 (2H, d), 6.81 (2H, d), 6.46 (1H, d, J=5.77 Hz), 6.23 (1H, br. s.), 4.74 (2H, s), 3.24 (1H, s).
A mixture of 3-hydroxy-1-(4-methoxybenzyl)pyrazin-2(1H)-one (2.0 g, 8.61 mmol), PyBOP (7.84 g, 15.07 mmol) and N,N-diisopropylethylamine (4.51 mL, 8 mmol) in DMF (40 mL) was stirred at RT under N2 for 3 hours whereupon 4-(trifluoromethoxy)benzenethiol (2.007 g, 10.33 mmol) was added. After having stirred for 18 additional hours, the reaction was diluted with saturated aq. NaHCO3 (65 ml) and was then extracted with EtOAc (60 ml). The EtOAc layer was dried over Na2SO4 and concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 75% EtOAc/hexane) to elute 1-(4-methoxybenzyl)-3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one (2.76 g, 6.42 mmol, 74.6% yield) as white solid. 1H NMR (400 MHz, chloroform-d) δ ppm 7.58 (2H, d, J=8.78 Hz), 7.21-7.35 (4H, m), 7.02 (1H, d, J=4.52 Hz), 6.90 (2H, d, J=8.78 Hz), 6.85 (1H, d, J=4.27 Hz), 5.03 (2H, s), 3.81 (3H, s).
A solution of 1-(4-methoxybenzyl)-3-(4-(trifluoromethoxy)phenylthio)-pyrazin-2(1H)-one (2.76 g, 6.76 mmol) in TFA (25 mL) was stirred at reflux for 2 days. Since LC-MS analysis revealed that 28% SM remained, the reaction was stirred for 7 days. After removal of the TFA under vacuum, the crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 100% EtOAc to elute 3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one (1.60 g, 5.27 mmol, 78% yield) as off-white solid. 1H NMR (400 MHz, chloroform-d) δ ppm 7.61 (2H, d, J=9.03 Hz), 7.29 (2H, d, J=7.78 Hz), 7.24 (1H, d, J=4.02 Hz), 7.07 (1H, d).
A mixture of 3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one (100 mg, 0.347 mmol), 1-(4-bromo-2-methylphenoxy)-2-methylpropan-2-ol (90 mg, 0.347 mmol), N1,N2-dimethylethane-1,2-diamine (92 mg, 1.041 mmol), copper(I) iodide (19.82 mg, 0.104 mmol) and K3PO4 (221 mg, 1.041 mmol) in dioxane (1.0 mL) was stirred at 115° C. in a sealed tube for 2 hours. After removal of the precipitate by filtration, the filtrate was concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 100% EtOAc) to elute 1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(4-(trifluoromethoxy)phenylthio)-pyrazin-2(1H)-one (18.65 mg, 0.040 mmol, 11.52% yield) as off-white solid. 1H NMR (500 MHz, methanol-d3) δ ppm 7.62-7.68 (2H, m), 7.37 (2H, d, J=7.97 Hz), 7.21-7.28 (3H, m), 7.16 (1H, d, J=4.40 Hz), 7.02 (1H, d, J=8.25 Hz), 3.84 (2H, s), 2.31 (3H, s), 1.36 (6H, s).
To a mixture of 2-(4-chlorophenyl)ethanol (1.246 g, 7.96 mmol) in THF was added 1.0 M sodium bis(trimethylsilyl)amide in THF (6.92 mL, 6.92 mmol). After stirring at RT under nitrogen for 18 hours, the reaction was diluted with a solution of saturated NaHCO3 (65 ml) and extracted with EtOAc 720 ml). The ethyl acetate layer was dried over Na2SO4 and concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 30% ethyl acetate) to elute 2-(4-chlorophenethoxy)-3-methoxypyrazine (1.25 g, 4.72 mmol, 68.3% yield) as clear oil. 1H NMR (500 MHz, CDCl3) δ ppm 7.61-7.64 (1H, m), 7.59-7.61 (1H, m), 7.26-7.30 (2H, m), 7.20-7.24 (2H, m), 7.15 (1H, d, J=8.52 Hz), 4.49-4.63 (2H, m), 4.02 (3H, s), 3.12 (2H, t, J=7.29 Hz).
A mixture of benzo[d]thiazole-2-thiol (1.264 g, 7.56 mmol), 2-(4-chlorophenethoxy)-3-methoxypyrazine (1.00 g, 3.78 mmol) and NaHCO3 (1.587 g, 18.89 mmol) in DMA (10 mL) was stirred at 135° C. for 6 hours. After cooling to RT, the mixture was diluted with a solution of saturated NaHCO3 (55 ml) and was then extracted with EtOAc (60 ml). The EtOAc layer was dried over Na2SO4 and concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 100% EtOAc) to elute 3-(4-chlorophenethoxy)pyrazin-2(1H)-one (477 mg, 1.808 mmol, 47.9% yield) as off-white solid. 1H NMR (400 MHz, chloroform-d) δ ppm 7.27-7.31 (2H, m), 7.19-7.25 (2H, m), 6.95 (1H, d, J=4.27 Hz), 6.89 (1H, d, J=4.52 Hz), 4.54 (2H, t, J=7.53 Hz), 3.14 (2H, t, J=7.40 Hz).
A mixture of 3-(4-chlorophenethoxy)pyrazin-2(1H)-one (25 mg, 0.100 mmol), K3PO4 (63.5 mg, 0.299 mmol), copper (1) iodide (18.99 mg, 0.100 mmol), 1-(4-bromophenoxy)-2-methylpropan-2-ol and N,N′-dimethylethylenediamine (0.032 mL, 0.299 mmol) in dioxane (1.0 mL) was stirred at 110° C. for 60 min. After removal of the precipitate by filtration, the filtrate was concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (CH2Cl2 to 10% MeOH/CH2Cl2) to elute 3-(4-chlorophenethoxy)-1-(4-(2-hydroxy-2-methylpropoxy)phenyl)pyrazin-2(1H)-one (31.82 mg, 0.073 mmol, 73.1% yield) as white solid. 1H NMR (500 MHz, chloroform-d) δ ppm 7.32 (2H, d), 7.23-7.29 (4 H, m), 7.02 (2H, d), 6.84 (2H, s), 4.51 (2H, t, J=7.29 Hz), 3.83 (2H, s), 3.13 (2H, t, J=7.15 Hz), 1.36 (6H, s).
1H NMR (400 MHz, MeOD) δ ppm 7.69(d, 2H), 7.38(d, 2H), 7.33(d, 1H), 7.18(m, 3H), 7.03(d, 1H), 4.09(s, 2H), 3.91(s, 3H), 2.93(m, 2H), 2.66(m, 2H).
1H NMR (400 MHz, MeOD) δ ppm 7.78(s, 4H), 7.34(s, 1H), 7.19(m, 3H), 7.03(d, 1H), 4.09(s, 2H), 3.90(s, 3H), 2.93-m, 2H), 2.66(m, 2H).
1H NMR (400 MHz, MeOD) δ ppm 7.78(d, 1H), 7.53(m, 3H), 7.30(m, 1H), 7.20(s, 1H), 7.12(m, 1H), 7.06(d, 1H), 3.91(s, 3H), 3.88(s, 2H), 1.36(s, 6H).
1H NMR (400 MHz, MeOD) δ ppm 7.85(d, 1H), 7.53(m, 3H), 7.21(m, 4H), 3.91(s, 3H), 3.88(s, 2H), 1.36(s, 6H).
1H NMR (400 MHz, MeOD) δ ppm 7.97(d, 1H), 7.85(d, 1H), 7.53(d, 2H), 7.35(t, 1H), 7.21(s, 1H), 7.16(m, 1H), 7.07(m, 1H), 3.91(s, 1H), 3.88(s, 2H), 1.36(s, 6H).
1H NMR (400 MHz, MeOD) δ ppm 7.68(d, 2H), 7.40(d, 2H), 7.28(s, 1H), 7.17(m, 1H), 6.97(d, 1H), 3.82(s, 1H), 2.96(m, 2H), 2.24(m, 1H), 2.81(m, 1H), 1.33(s, 6H).
1H NMR (400 MHz, MeOD) δ ppm 7.69(d, 2H), 7.40(d, 2H), 7.28(m, 2H), 7.20(m, 2H), 6.91(d, 1H), 5.79(s, 1H), 4.70(s, 1H), 2.08(s, 2H), 1.31(d, 6H).
1H NMR (400 MHz, CDCl3) δ ppm 7.61(d, 2H), 7.59(s, 1H), 7.28(m, 2H), 7.14(m, 2H), 6.99(s, 1H), 6.92(d, 1H), 4.87(t, 1H), 4.00(d, 1H), 2.36(m, 1H), 1.84(q, 1H), 1.38(d, 6H).
1H NMR (400 MHz, MeOD) δ ppm 7.70(d, 2H), 7.61(s, 1H), 7.43(d, 2H), 7.28(m, 2H), 7.20(s, 1H), 6.95(d, 1H), 4.35(m, 2H), 2.12(br-s, 2H), 1.62(s, 3H).
1H NMR (500 MHz, chloroform- d) δ ppm 7.62(2 H, d, J = 8.80 Hz), 7.36(2 H, d, J = 8.80 Hz), 7.29(2 H, d, J = 7.97 Hz), 7.13(1 H, d, J = 4.67 Hz), 7.04(2 H, d, J = 8.80 Hz), 6.98(1 H, d, J = 4.40 Hz), 3.84(2 H, s), 1.37(6 H, s).
1H NMR (500 MHz, chloroform- d) δ ppm 8.31(1 H, dd, J = 6.19, 3.44 Hz), 8.00(1 H, d, J = 8.25 Hz), 7.85-7.95(2 H, m), 7.51-7.56(3 H, m), 7.04(1 H, d, J = 2.20 Hz), 6.97-7.02(1 H, m), 6.89-6.96(3 H, m), 3.90(3 H, s), 3.88(2 H, s), 1.37(6 H, s).
1H NMR (500 MHz, methanol-d3) δ ppm 7.62-7.68(2 H, m), 7.34- 7.39(3 H, m), 7.21-7.29(3 H, m), 7.15(1 H, d, J = 4.40 Hz), 3.91 (2 H, s), 1.34(6 H, s).
1H NMR (500 MHz, methanol-d3) δ ppm 7.62-7.69(2 H, m), 7.36(2 H, d, J = 7.97 Hz), 7.21-7.28(3 H, m), 7.15(1 H, d, J = 4.40 Hz), 7.02(1 H, d, J = 8.52 Hz), 3.84(2 H, s), 2.31(3 H, s), 1.36(6 H, s).
1H NMR (500 MHz, methanol- d3) δ ppm 7.65(2 H, d, J = 8.80 Hz), 7.59(1 H, d, J = 2.75 Hz), 7.33-7.41(3 H, m), 7.27(1 H, d, J = 4.40 Hz), 7.22(1 H, d, J = 8.80 Hz), 7.15(1 H, d, J = 4.40 Hz), 3.91(2 H, s), 1.37(6 H, s)
1H NMR (500 MHz, methanol-d3) δ ppm 7.66(2 H, d), 7.52-7.56(1H, m), 7.46(1 H, dd, J = 8.94, 2.61 Hz), 7.37(2 H, d, J = 7.97 Hz), 7.33 (1 H, d, J = 8.80 Hz), 7.29(1 H, d, J = 4.40 Hz), 7.16(1 H, d, J = 4.67 Hz), 3.91(2 H, s), 1.34(6 H, s).
1H NMR (500 MHz, methanol-d3) δ ppm 7.85(1 H, d, J = 2.75 Hz), 7.74(1 H, dd, J = 8.94, 2.61 Hz), 7.65(2 H, d), 7.33-7.39(3 H, m), 7.29(1 H, d, J = 4.67 Hz), 7.16(1 H, d, J = 4.40 Hz), 4.01(2 H, s), 1.38(6 H, s).
1H NMR (500 MHz, methanol-d3) δ ppm 7.65(2 H, d, J = 8.80 Hz), 7.37 (2 H, d, J = 7.97 Hz), 7.24-7.32 (3 H, m), 7.15(1 H, d, J = 1.40 Hz), 4.00(2 H, s), 1.33(6 H, s).
Prodrugs were prepared of selected secondary and tertiary alcohols to improve solubility and exposure. Standard conditions, employed to generate amino acid esters of all but the glycine ester of the tertiary alcohols, are exemplified in Example 193. Preparation of the glycine ester of the tertiary alcohols is exemplified in Example 202. Preparation of a phosphate ester prodrug is exemplified by Example 204.
To a stirred suspension of the alcohol prepared in Example 36 (3.0 g, 6.4 mmol), 4-pyrrolidinopyridine (0.95 g, 6.4 mmol) and BOC-glycine (3.4 g, 19 mmol) in CH2Cl2 (60 mL) at 42° C. was added N,N′-diisopropylcarbodiimide 3.0 mL, 19 mmol) over 3.5 h. After stirring at reflux for 2.5 h, HPLC analysis showed 25% alcohol still remained. More BOC-glycine (3.4 g, 19 mmol) was added followed by additional N,N′-diisopropylcarbodiimide (3.0 mL, 19 mmol) which was slowly added over 3.5 h; whereupon, HPLC analysis showed <5% alcohol remained. The reaction was allowed to cool to RT prior to addition of hydrazine monohydrate (18 mL, 370 mmol). After stirring for 5 minutes, the reaction mixture was cooled to 0° C. and filtered. The filtrates were sequentially washed with cold 1M HCl (3×20 mL) and cold 2% NaHCO3 (3×20 mL) prior to drying over MgSO4 and concentrating under vacuum to afford 5.6 g of crude product. Chromatography (silica gel 230-400 mesh, gradient elution: 0 to 60% EtOAc/hexane over 47 min) of the residue afforded the desired ester (3.9 g, 88% yield). HPLC 4.42 min. LC MS (M+1=624), H-NMR (CDCl3) 7.72 (m, 4H), 7.12 (d, J=4.4 Hz, 1H), 7.02 (d, J=4.4 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.99 (d, J=2.5 Hz, 1H), 6.90 (dd, J=2.5 and 8.3 Hz, 1H), 4.21 (s, 2H), 3.87 (s, 3H), 3.78 (m, 2H), 1.61 (s, 6H), 1.45 (s, 9H).
The BOC'd glycinate ester described in Part A (3.9 g, 6.2 mmol) was treated with 1:2 TFA/CH2Cl2 (145 mL) at RT for 25 min. After removal of the volatiles under vacuum, the residual TFA was removed by co-evaporation with CH2Cl2 (3×8 mL) and drying under vacuum for 20 min. Following dissolution in CH2Cl2 (70 mL), the solution was washed with cold 5% NaHCO3 (3×30 mL) dried over MgSO4 and concentrated to yield 3.3 g of crude product. Purification by flash chromatography (120 g silica gel, 0 to 5% MeOH/CH2Cl2 over 24 min) afforded the desired free amine (2.5 g, 77% yield).). HPLC 3.72 min. LC MS 2.18 min (M+1=524), H-NMR (CDCl3) 7.75 (d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 7.14 (d, J=4.4 Hz, 1H), 7.02 (d, J=4.4 Hz, 1H), 7.00 (d, J=8.5 Hz, 1H), 6.99 (d, J=2.4 Hz, 1H), 6.92 (dd, J=2.4 and 8.5 Hz, 1H), 4.24 (s, 2H), 3.89 (s, 3H), 3.36 (m, 2H), 1.63 (s, 6H), 1.54 (broad s, 2H).
Examples 194 to 201 were prepared in a similar manner to Example 193 using the appropriate alcohol and BOC glycine followed by TFA removal of the BOC group.
1H-NMR
If desired the amino acid prodrug esters may be converted to the corresponding HCl salt. For example, the HCl salt of Example 197 was prepared by dissolving the compound (0.655 mg, 1.36 mmoles) in CH2Cl2 (10 mL) and MeOH (1 mL) and cooling to −30° C. 1N HCl in ether (2.3 mL, 1.7 eq) was added with stirring. Evaporation in vacuo afforded the desired salt. (0.71 g). LC MS was identical to the free base. H-NMR (CD3OD) 7.30 (d, J=4.4 Hz, 1H), 7.20 (m, 4H), 7.13 (m, 4H), 6.93 (d, J=8.5 Hz, 1H), 4.19 (s, 2H), 3.64 (s, 2H), 3.23 (dd, J=7.4, 15.4 Hz, 2H), 2.90 (dd, J=8.0 and 15.4 Hz, 2H), 2.62 (q, J=7.5 Hz, 2H), 1.59 (s, 6H), 1.14 (t, J=7.5 Hz, 3H).
To a stirred mixture of the alcohol described in Example 71 (0.882 g, 1.949 mmol), 4-dimethylaminopyridine (0.714 g, 5.85 mmol) and N-(t-butoxycarbonyl)-L-valine (1.271 g, 5.85 mmol) in 18 mL of CH2Cl2 at rt was added WSC (1.121 g, 5.85 mmol). After stirring at ambient temperature for 30 min, the reaction mixture was transferred to a separatory funnel, washed with cold 5% H2SO4 (3×), 5% Na2CO3 (2×), and water and dried over MgSO4. Evaporation of the solvent afforded 1.03 g of crude product as the BOC amine. The crude product was dissolved in a 1:2 mixture of TFA/CH2Cl2 (18 mL). After stirring for 15 min the solvent was evaporated in vacuo. The residue was transferred to a separatory funnel with CH2Cl2, washed with cold 5% Na2CO3 (2×), and dried over MgSO4 to afford crude 790 mg of product after evaporation of the solvent. The product was purified by flash chromatography (80 g silica gel, gradient elution: 1 to 8% MeOH/CH2Cl2 over 24 min) to afforded the desired valine ester as a free base (0.69 g, 64% yield).
HPLC (Method 1) 3.84 min. LC MS 2.26 min (M+1=552), H-NMR (CDCl3) 7.74 (d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 7.13 (d, J=4.4 Hz, 1H), 7.02 (d, J=4.4 Hz, 1H), 7.00 (d, J=8.5 Hz, 1H), 6.99 (d, J=2.4 Hz, 1H), 6.91 (dd, J=2.4 and 8.5 Hz, 1H), 5.34 (m, 1H), 4.12 (m, 2H), 3.86 (d, 3H), 3.30 (t, J=5.2 Hz, 1H), 2.05 (m, 1H), 1.40 (d, J=6.4 Hz), 0.98 (m, 3H), 0.92 (m, 3H).
The HCl salt of Example 176 was prepared by dissolving the compound in CH2Cl2 (9 mL). After cooling the solution to −30° C., 1N HCl in ether (2.85 mL, 1.7 eq) was added with stirring. The yellow precipitate was collected and dried to afford the HCl salt (0.74 g).
LC MS was identical to the free base. H-NMR (CDCl3) 7.74 (d, J=8.7 Hz, 2H), 7.79 (m, 4H), 7.33 (d, J=4.4 Hz, 1H), 7.18 (d, J=8.5 Hz, 1H), 7.15 (d, J=2.4 Hz, 1H), 7.02 (dd, J=2.4 and 8.5 Hz, 1H), 5.51 (m, 1H), 4.24 (m, 2H), 3.86 (d, 3H), 3.33 (s, 1H), 2.30 (m, 1H), 1.41 (d, J=6.4 Hz), 1.12 (m, 6H).
In an analogous fashion to that described in Example 202, the valine ester of the alcohol described in Example 74 was prepared.
LC MS at t=2.35 min. (m+1=606) Phenomenex S5 C18 4.6×30 mm column/water-MeOH-TFA 90:10:0.1 to 10:90:0.1 gradient over 2 min at 5 mL/min with 1 min hold at the end of the gradient.
1H NMR (500 MHz, CDCl3) δ ppm 0.97 (dd, J=35.13, 6.92 Hz, 6H), 1.97-2.20 (m, 1H), 3.42 (d, J=4.78 Hz, 1H), 3.86 (s, 4H), 4.26-4.36 (m, 1H), 4.44 (dd, J=11.08, 3.53 Hz, 1H), 5.73-5.87 (m, 1H), 6.91 (dd, J=8.56, 2.27 Hz, 1H), 6.97-7.06 (m, 2H), 7.13 (d, J=4.53 Hz, 1H), 7.58 (s, 1H), 7.66-7.77 (m, 4H).
To a mixture of dibenzyl diisopropylphosphoramidite (135 mg, 0.390 mmol), 1-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)-3-(4-(trifluoromethoxy)phenylthio)pyrazin-2(1H)-one (Example 75) (69 mg, 0.130 mmol) and 1H-1,2,4-triazole (27.0 mg, 0.390 mmol) in DCE (20 mL) was stirred at reflux for 6 hours. The mixture was cooled to RT. 30% hydrogen peroxide in water (10 ml) was slowly added and the mixture was stirred at RT for 30 min. The mixture was diluted with a solution of aqueous 10% sodium thiosulfate (40 ml) and was extracted with DCM (50 ml). The DCM layer was dried over sodium sulfate and concentrated.
The crude product was purified by ISCO silica gel Column (40 g) and the product was eluted with hexane to 100% ethyl acetate in 10 min. Yield dibenzyl 3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylthio)pyrazin-1(2H)-yl)phenoxy)methyl)cyclobutyl phosphate (79 mg, 0.100 mmol, 77% yield) as off-white solid. 1H NMR (400 MHz, chloroform-d) δ ppm 7.57-7.66 (2H, m), 7.27-7.39 (12 H, m), 7.13 (1H, d, J=4.53 Hz), 6.81-7.00 (4H, m), 4.97-5.14 (4H, m), 4.29 (2H, s), 3.75 (3H, s), 2.93-3.20 (4H, m).
To a solution of dibenzyl 3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylthio)pyrazin-1(2H)-yl)phenoxy)methyl)cyclobutyl phosphate (79 mg, 0.100 mmol) in TFA (2 mL) was stirred at RT for 3.5 hours. The mixture was concentrated. The crude product was purified by prep-HPLC (Phenomenex, Luna 5 micron 25×250 mm, flow rate=30 ml/min., gradient=20% A to 100% B in 10 min., A=90% H2O/10% MeOH/0.1% TFA, B=10% H2O/90% MeOH/0.1% TFA). Yield 46 mg, 0.075 mmol as yellow gum. The yellow gum in ACN (2 ml) was added 0.5 N aqueous sodium bicarbonate (302 μl, 0.151 mmol), the mixture was diluted with water (5 ml). The solution was then lyophilized. Yield sodium 3,3-difluoro-1-((2-methoxy-4-(2-oxo-3-(4-(trifluoromethoxy)phenylthio)pyrazin-1(2H)-yl)phenoxy)methyl)cyclobutyl phosphate (51.08 mg, 0.078 mmol, 78% yield) as off-white powder. MS (M+H=611). 1H NMR (400 MHz, MeOD) δ ppm 7.54-7.63 (2H, m), 7.19-7.33 (3 H, m), 7.02-7.17 (3H, m), 6.91 (1H, dd, J=8.44, 2.39 Hz), 4.28 (2H, s), 3.80 (3H, s), 3.13-3.32 (2H, m), 2.75-2.90 (2H, m).
In an analogous fashion to that described in Example 204, the phosphate prodrug of the alcohol described in Example 38 was prepared. MS (M−H=561). 1H NMR (400 MHz, MeOD) δ ppm 7.57 (2H, d, J=8.56 Hz), 7.28 (2H, d, J=8.31 Hz), 7.20 (1H, d, J=4.28 Hz), 6.97-7.12 (3H, m), 6.88 (1H, dd, J=8.56, 2.27 Hz), 4.00 (2H, s), 3.78 (3H, s), 1.48 (6H, s).
The following experimental descriptions exemplify the preparation of specific compounds as set out in Examples 27, 95, 110, 113, and 124.
Following the procedures described in parts A-D of example 134, 2-methoxy-4-nitrophenol was converted to 1-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)pyrazine-2,3(1H,4H)-dione. A solution of 1-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)pyrazine-2,3(1H,4H)-dione prepared in Part ? (2.28 g, 7.44 mmol), EtN(iPr)2 (3.9 mL, 22.3 mmol), PyBOP (6.78 g, 13.0 mmol) in DMF (35 mL) was stirred at ambient temperature for 1.5 h. After addition of 2-pyridylethyl mercaptan (1.24 g, 8.93 mmol), the reaction was stirred at ambient temperature. After stirring overnight the reaction mixture was partially concentrated under reduced pressure, quenching by addition of aq. NaHCO3 and extracted with EtOAc. The EtOAc extracts were washed with brine, dried over MgSO4 and concentrated. Chromatography on silica employing a gradient elution with 2.5-10% methanol/methylene chloride, followed by chromatography on silica eluting with EtOAc, and trituration with EtOAc/Hexanes afforded the desired product 1-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)-3-(2-(pyridin-2-yl)ethylthio)pyrazin-2(1H)-one (2.15 g, 68% yield).
A mixture of 2-methyl-4-nitrophenol (5.50 g, 35.9 mmol), 2,2-dimethyloxirane (7.77 g, 108 mmol), K2CO3 (4.96 g, 35.9 mmol) and NaH2PO4 (4.31 g, 35.9 mmol) in MeCN (50 mL) and H2O (8.82 mL) was stirred at 140° C. in a steel bomb for 6 hours. After cooling to RT, the reaction was diluted with aq. saturated NaHCO3 (80 ml) prior to extraction with EtOAc (100 ml). The EtOAc layer was dried over Na2SO4 and concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 60% ethyl acetate) to elute 2-methyl-1-(2-methyl-4-nitrophenoxy)propan-2-ol (7.3 g, 32.4 mmol, 90% yield) as yellow oil. MS (M+1=226). 1H NMR (500 MHz, chloroform-d) δ ppm 8.00-8.15 (2H, m), 6.86 (1H, d, J=8.80 Hz), 3.90 (2H, s), 2.33 (3H, s), 1.40 (6H, s).
A mixture of 2-methyl-1-(2-methyl-4-nitrophenoxy)propan-2-ol (7.30 g, 32.4 mmol) and 10% Pd/C (0.345 g, 3.24 mmol) in MeOH (150 mL) was hydrogenated at 1 atm of H2 for 18 hours. After removal of the Pd/C by filtration, the solution was concentrated to yield 1-(4-amino-2-methylphenoxy)-2-methylpropan-2-ol (6.10 g, 29.7 mmol, 92% yield) as clear gum which was carried forward without further purification.
Slow addition of a solution of ethyl 2-chloro-2-oxoacetate (4.69 g, 34.4 mmol) in THF (30 ml) to a solution of 1-(4-amino-2-methylphenoxy)-2-methylpropan-2-ol (6.10 g, 31.2 mmol) in THF (100 mL) resulted in formation of a precipitate as the reaction stirred at RT for 30 min. At which time a solution of Et3N (13.06 mL, 94 mmol) and 2,2-dimethoxyethanamine (3.94 g, 37.5 mmol) in EtOAc (100 mL) was added prior to heating the mixture at reflux for 25 hours. After cooling and concentration under vacuum, the residue, following dilution with CH2Cl2, was extracted with aqueous 0.5 N HCl (2×150 ml). The CH2Cl2 layer was dried over sodium sulfate and concentrated to yield N1-(2,2-dimethoxyethyl)-N2-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-oxalamide (11.40 g, 30.6 mmol, 98% yield) as white solid which was carried forward without further purification.
A solution of N1-(2,2-dimethoxyethyl)-N2-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)oxalamide (11.4 g, 32.2 mmol) and TFA (2.97 mL, 38.6 mmol) in AcOH (120 mL) was stirred at 135° C. in a seal tube for 60 min. After cooling and concentration under vacuum, addition of CH2Cl2 (300 ml) produced a precipitate which was collected by filtration and was washed with CH2Cl2 (150 ml) to yield 3-hydroxy-1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)pyrazin-2(1H)-one (7.19 g, 23.53 mmol, 73.1% yield) as brown solid. MS (M+1=226). 1H NMR (500 MHz, methanol-d3) δ ppm 7.13-7.26 (2H, m), 6.98 (1H, d, J=8.52 Hz), 6.50 (1H, d, J=5.77 Hz), 6.41 (1H, d, J=6.05 Hz), 3.82 (2H, s), 2.29 (3H, s), 1.35 (6H, s).
A mixture of 3-hydroxy-1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)pyrazin-2(1H)-one (100 mg, 0.344 mmol), PyBOP (314 mg, 0.603 mmol) and EtN(iPr)2 (0.180 mL, 1.033 mmol) in DMF (6 mL) was stirred at RT for 3 hours prior to addition of 5-(trifluoromethyl)pyridine-2-thiol (74.1 mg, 0.413 mmol). After stirring for 3 days, The reaction was diluted with aq. saturated NaHCO3 (15 ml) prior to extraction with EtOAc (20 ml). The EtOAc layer was dried over Na2SO4 and concentrated. The crude product was purified by prep-HPLC (Phenomenex, Luna 5 micron 30×250 mm, flow rate=30 ml/min., gradient=20% A to 100% B in 30 min., A=90% H2O/10% MeOH/0.1% TFA, B=10% H2O/90% MeOH/0.1% TFA). After concentration, the residue in EtOAc (30 ml) was converted to the free base by washing with aq. saturated NaHCO3 (30 ml). The EtOAc layer was dried over Na2SO4 and concentrated. To yield 1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(5-(trifluoromethyl)pyridin-2-ylthio)pyrazin-2(1H)-one (22.76 mg, 14%) as off-white solid. MS (M+1=452). 1H NMR (500 MHz, chloroform-d) δ ppm 8.88 (1H, s), 7.89-7.99 (2H, m), 7.16-7.24 (3H, m), 7.07 (1H, d, J=4.40 Hz), 6.90 (1H, d, J=8.52 Hz), 3.84 (2H, s), 2.30 (3H, s), 1.39 (6H, s).
A mixture of 3-(2-(pyridin-2-yl)ethylthio)pyrazin-2(1H)-one (100 mg, 0.429 mmol), which was prepared by the procedure described in Method 7 except for substitution of 2-(2-pyridylethylthiol) for 2-(4-chlorophenethanol), 1-(4-bromo-2-methylphenoxy)-2-methylpropan-2-ol (133 mg, 0.514 mmol), N1,N2-dimethylethane-1,2-diamine (113 mg, 1.286 mmol), K3PO4 (0.106 mL, 1.286 mmol) and copper(1) iodide (82 mg, 0.429 mmol) in dioxane (1.0 mL) was stirred at 115° C. for 90 min. The reaction mixture, after cooling to RT, was filtered and the filtrate was concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 100% ethyl acetate) to yield 1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(2-(pyridin-2-yl)ethylthio)pyrazin-2(1H)-one (140 mg, 0.340 mmol, 79% yield) as white solid. MS (M+H 412). 1H NMR (400 MHz, MeOD) δ ppm 8.67 (1H, d), 8.48 (1H, td, J=7.91, 1.51 Hz), 8.02 (1H, d, J=8.28 Hz), 7.81-7.95 (1H, m), 7.07-7.29 (4H, m), 6.93 (1H, d, J=8.78 Hz), 3.76 (2H, s), 3.35-3.57 (4H, m), 2.22 (3H, s), 1.27 (6H, s).
A mixture of 3-(phenethylthio)pyrazin-2(1H)-one (25 mg, 0.108 mmol), which was prepared by the procedure described in Method 7 except for substitution of 2-phenethylthiol for 2-(4-chlorophenethanol), 1-(4-bromo-2-methylphenoxy)-2-methylpropan-2-ol (33.5 mg, 0.129 mmol), copper iodide (20.50 mg, 0.108 mmol), K3PO4 (70 mg, 0.323 mmol) and N,N′-dimethylethylenediamine (28.5 mg, 0.323 mmol) in dioxane (1.0 ml) was stirred at 115° C. for 2 hours. The reaction mixture, after cooling to RT, was filtered and the filtrate was concentrated. The crude product was purified by silica gel chromatography employing a solvent gradient (hexane to 100% ethyl acetate) to elute to yield 1-(4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl)-3-(phenethylthio)-pyrazin-2(1H)-one (26.74 mg, 0.062 mmol, 57.5% yield) as off-white solid. MS (M+1=411). 1H NMR (500 MHz, methanol-d3) δ ppm 7.38 (1H, d, J=4.40 Hz), 7.25-7.32 (4H, m), 7.16-7.24 (4H, m), 7.00 (1H, d, J=8.25 Hz), 3.83 (1H, s), 3.24-3.39 (2H, m), 2.90-3.05 (2H, m), 2.29 (3H, s), 1.35 (6H, s).
Compounds of Formula I were initially characterized in an in vitro binding assay to determine their Ki or ability to antagonize binding of a peptide agonist to the human melanin concentrating hormone receptor (MCHR1).
Membranes from stably transfected HEK-293 cells expressing a mutated (E4Q, AST) hMCHR1 receptor were prepared by dounce homogenization and differential centrifugation. Binding experiments were carried out with 0.5-1.0 ug of membrane protein incubated in a total of 0.2 ml in 25 mM HEPES (pH 7.4) with 10 mM MgCl2, 2 mM EGTA, and 0.1% BSA (Binding Buffer) for 90 min. For competition binding assays, reactions were carried out in the presence of with 0.06-0.1 nM [Phen, [125I]Tyr19]-MCH and increasing concentrations of unlabeled test molecules. Reactions were terminated by rapid vacuum filtration over 96 well-GFC Unifilter plates pre-coated with 0.075 ml binding buffer containing 1% BSA, and washed 3 times with 0.4 ml of Phospho-buffered Saline (pH 7.4) containing 0.01% TX-100. Filters were dried; 0.05 ml microscint 20 was added to each well and radioactivity was subsequently quantified by scintillation counting on a TopCount™ microplate scintillation counter (Packard). Inhibitory constants were determined by nonlinear least squares analysis using a four parameter logistic equation.
The following representative in vitro biological data was measured in a binding assay for the compounds from the Examples herein above:
The relative ability of the prodrug to enhance exposure (bioavailability) was assessed in an eight hour PK study using cannulated Sprague Dawley (CD, Charles River Breeding Laboratory) rats. The compounds (parent and prodrug esters) were administered p.o. at 2.0 ml/kg as a suspension in 0.5% methyl cellulose, 0.1% Tween 80 in water at 10 mg/kg p.o. Blood samples were taken at 1, 2, 4 and 8 hr. After determination of parent concentration, an AUC was calculated for the eight hour study.
Male Sprague Dawley (CD, Charles River Breeding Laboratory) rats weighing approximately 240 grams were placed in individual plastic cages with AlphaDri bedding. The room was maintained at 72° F. and 50% humidity, and a 12/12 light dark cycle with lights out at 1600 hours. The rats were conditioned for 5 days prior to the start of the study to having a choice of foods. A normal chow (Harlan Teklad, 2018) that contains 18% protein, 5% fat and 73% carbohydrate and a high fat high sugar diet (Research Diets (D2327) that contains 20% protein, 40% fat and 40% carbohydrate where the carbohydrate is entirely sucrose and the fat is soybean and coconut oil. Studies have revealed that rats exhibit a high preference for the high fat/high sucrose diet (80% preference). Body weight and consumption of both kinds of food as well as water intake were measured daily. Water was available ad lib throughout the study. Food consumption is presented as daily caloric consumption which is the sum of grams of chow multiplied by the Kcal per gram (3.5) plus grams of high fat high sugar multiplied by Kcal per gram (4.59).
Baseline body weight was measured prior to drug treatment on day 0 of the study. Baseline food consumption was the average of the 3 days prior to the first drug treatment. Drug was administered daily p.o. at 2.0 ml/kg at 1500 hours beginning on day 0 and continuing daily through day 4 as a suspension in 0.5% methyl cellulose, 0.1% Tween 80 in water at 3.0, 10 and 30 mg/kg p.o. All data were evaluated using ANOVA and Fishers PLSD statistics.
While the invention has been described according to several embodiments, various modifications thereto, in addition to those described herein, may become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
This application is a continuation of U.S. Ser. No. 12/141,228 filed Jun. 18, 2008 which claims the benefit of U.S. Provisional Application Ser. No. 60/948,213 filed Jul. 6, 2007.
| Number | Date | Country | |
|---|---|---|---|
| 60948213 | Jul 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12141228 | Jun 2008 | US |
| Child | 12881234 | US |
